Investigating the in vivo bioequivalence of losartan 50 mg
Not Applicable
Recruiting
- Conditions
- In the present study, the products will be administered to healthy volunteers..
- Registration Number
- IRCT20220211053992N4
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
General Health (in terms of Liver, Heart and Kidney)
Exclusion Criteria
Smoking
History of cardiovascular disease, liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of drug. Timepoint: 0.5-24 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie losartan's AT1 receptor antagonism in IRCT20220211053992N4 bioequivalence trial?
How does Hakim Co.'s losartan 50 mg compare to the innovator in plasma concentration-time profiles for hypertension management?
Are there biomarkers like AGT or ACE polymorphisms predicting losartan response in cardiovascular drug development?
What adverse event profiles differentiate generic and innovator losartan in healthy volunteers during pharmacokinetic studies?
How do ARB class effects of losartan compare with other angiotensin receptor blockers like valsartan in bioequivalence research?